Repositori DSpace/Manakin

Impact of Obstructive Sleep Apnea (OSA) in COVID-19 Survivors, Symptoms Changes Between 4-Months and 1 Year After the COVID-19 Infection

Mostra el registre parcial de l'element

dc.creator Labarca, Gonzalo
dc.creator Henríquez Beltrán, Mario
dc.creator Lamperti, Liliana
dc.creator Nova Lamperti, Estefania
dc.creator Sanhueza, Sergio
dc.creator Cabrera, Camilo
dc.creator Quiroga, Romina
dc.creator Antilef, Barbara
dc.creator Ormazábal, Valeska
dc.creator Zúñiga, Felipe
dc.creator Castillo, Daniela
dc.creator Horta, Gloria
dc.creator Enos, Daniel
dc.creator Lastra, Jaime
dc.creator González, Jessica
dc.creator Targa, Adriano
dc.creator Barbé Illa, Ferran
dc.date 2022
dc.date.accessioned 2025-11-03T12:17:16Z
dc.date.available 2025-11-03T12:17:16Z
dc.identifier https://doi.org/10.3389/fmed.2022.884218
dc.identifier 2296-858X
dc.identifier http://hdl.handle.net/10459.1/83668
dc.identifier.uri http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/24348
dc.description Objective: To determine the association between Obstructive Sleep Apnea (OSA) with long-term symptoms and inflammatory cytokines, exploring the changes between 4-months and 1-year after COVID-19 infection. Methods: We conducted an observational, prospective cohort study, including patients ≥18 years old with confirmed diagnosis of COVID-19 between April to July 2020. All participants underwent two clinical follow-up visits, the first at 4-months (Visit 1) and the second at 1 year, after SARS-CoV-2 infection (Visit 2). Plasma glucose, total cholesterol, HDL, and triglycerides. Regarding pulmonary function, spirometry and lung diffusion capacity tests were assessed. For mental and neurocognitive evaluation, a short-form (SF-12), Beck depression and Hospital-Anxiety depression questionnaires were conducted at both time-points, whereas the Montreal Cognitive assessment was conducted during the second follow-up. Regarding to sleep evaluation, Epworth Sleepiness Scale, Insomnia Severity index and STOP-BANG questionnaire were conducted. Additionally, a home sleep apnea test and 7-day wrist actigraphy were performed in all participants. Inflammatory cytokines were measured using an inflammatory cytokine bead array kit. p-values < 0.05 were considered statistically significant and statistical analyses were performed using R software. Results: A total of 60 patients were included in the first follow-up, from which 57 completed the second follow-up. The mean age was 46.4 years-old (SD ± 13.1) and 53.3% were male. 30% of cases reported mild COVID-19 infection, 28.3% with moderate illness, and 41.6% with severe illness. Moreover, 56.6% of them were admitted to the ICU. Regarding to metabolic values, the OSA group showed higher values of insulin resistance (IR) (27%), systolic blood pressure (SBP) 135.2 (±19.1), dyslipidemia (67.5%), total cholesterol 202.1 (±60.5), triglycerides 176.1 (±119.0) and HOMA-IR 9.0 (±18.8) in comparison with the non-OSA group. 1 year after COVID-19 infection, DLCO test remains abnormal in OSA patients (25% OSA vs. 3.6% non-OSA, p = 0.02). Finally, those participants with OSA who develop ARDS reported an adjusted OR 20.4 (95%-CI, 1.04-504) risk of neurocognitive impairment. Discussion: Among patients with previous COVID-19, OSA impact the development of incident glycemic, neurocognitive impairment, and abnormal functional pulmonary changes that persist up to 1 year since acute phase.
dc.description This study was supported by the Agencia Nacional de Investigación y Desarrollo (ANID, COVID1005), Chilean Government. GL declares funding for research by the American Academy of Sleep Medicine (AASM, 254-FP-21). JG, FB, and AT declare funded by ISCIII (CIBERESUCICOVID, COV20/00110). EN-L, SS, CC, RQ and BA were funded by Fondecyt 1211480 and COVID-19 Genomics Network (C19-GenoNet) ACT210085. Figure 1 was created with BioRender.com and Flow Cytometer was funded by EQM150061 (FONDEQUIP-ANID).
dc.language eng
dc.publisher Frontiers Media
dc.relation Reproducció del document publicat a: https://doi.org/10.3389/fmed.2022.884218
dc.relation Frontiers in Medicine, 2022, vol. 9
dc.rights cc-by (c) Authors 2022
dc.rights info:eu-repo/semantics/openAccess
dc.rights http://creativecommons.org/licenses/by/4.0/
dc.subject COVID-19
dc.subject Cytokines
dc.subject Neurocognitive impairment
dc.subject Obstructive sleep apnea
dc.subject Symptoms
dc.title Impact of Obstructive Sleep Apnea (OSA) in COVID-19 Survivors, Symptoms Changes Between 4-Months and 1 Year After the COVID-19 Infection
dc.type info:eu-repo/semantics/article
dc.type info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

Fitxers Grandària Format Visualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a DSpace


Cerca avançada

Visualitza

El meu compte